EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Genome‐Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1 , UGT1A3 , and LPP

Anssi J H Mykkänen iD, E Katriina Tarkiainen, Suvi Taskinen, Mikko Neuvonen iD, Maria Paile-Hyvärinen iD, Tuomas O Lilius iD, Tuija Tapaninen iD, Kathrin Klein, Matthias Schwab iD, Janne T Backman iD, Aleksi Tornio iD, Mikko Niemi iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Anssi J H Mykkänen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Area Under Curve, Atorvastatin, Cytochrome P-450 CYP3A, Genome-Wide Association Study. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Research Council, Sigrid Juséliuksen Säätiö, Robert Bosch Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In a genome‐wide association study of atorvastatin pharmacokinetics in 158 healthy volunteers, the SLCO1B1 c.521T>C (rs4149056) variant associated with increased area under the plasma concentration‐time curve from time zero to infinity (AUC 0–∞ ) of atorvastatin ( P = 1.2 × 10 −10 ), 2‐hydroxy atorvastatin ( P = 4.0 × 10 −8 ), and 4‐hydroxy atorvastatin ( P = 2.9 × 10 −8 ). An intronic LPP variant, rs1975991, associated with reduced atorvastatin lactone AUC 0–∞ ( P = 3.8 × 10 −8 ). Three UGT1A variants linked with UGT1A3*2 associated with increased 2‐hydroxy atorvastatin lactone AUC 0–∞ ( P = 3.9 × 10 −8 ). Furthermore, a candidate gene analysis including 243 participants suggested that increased function SLCO1B1 variants and decreased activity CYP3A4 variants affect atorvastatin pharmacokinetics. Compared with individuals with normal function SLCO1B1 genotype, atorvastatin AUC 0–∞ was 145% (90% confidence interval: 98‐203%; P = 5.6 × 10 −11 ) larger in individuals with poor function, 24% (9‐41%; P = 0.0053) larger in those with decreased function, and 41% (16‐59%; P = 0.016) smaller in those with highly increased function SLCO1B1 genotype. Individuals with intermediate metabolizer CYP3A4 genotype ( CYP3A4*2 or CYP3A4*22 heterozygotes) had 33% (14‐55%; P = 0.022) larger atorvastatin AUC 0–∞ than those with normal metabolizer genotype. UGT1A3*2 heterozygotes had 16% (5‐25%; P = 0.017) smaller and LPP rs1975991 homozygotes had 34% (22‐44%; P = 4.8 × 10 −5 ) smaller atorvastatin AUC 0‐∞ than noncarriers. These data demonstrate that genetic variation in SLCO1B1 , UGT1A3 , LPP , and CYP3A4 affects atorvastatin pharmacokinetics. This is the first study to suggest that LPP rs1975991 may reduce atorvastatin exposure. [Correction added on 6 April, after first online publication: An incomplete sentence (“= 0.017) smaller in heterozygotes for UGT1A3*2 and 34% (22%, 44%; P × 10 −5 ) smaller in homozygotes for LPP noncarriers.”) has been corrected in this version.]

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Area Under CurveAtorvastatinCytochrome P-450 CYP3AGenome-Wide Association StudyGlucuronosyltransferaseLiver-Specific Organic Anion Transporter 1Polymorphism, Single NucleotideAdultFemaleHumansMaleMiddle AgedYoung AdultGenotypeHealthy VolunteersHydroxymethylglutaryl-CoA Reductase InhibitorsPharmacogenomic VariantsLIM Domain ProteinsCytoskeletal Proteins

Substanzen

AtorvastatinCYP3A4 protein, humanCytochrome P-450 CYP3AGlucuronosyltransferaseHydroxymethylglutaryl-CoA Reductase InhibitorsLiver-Specific Organic Anion Transporter 1SLCO1B1 protein, humanUDP-glucuronosyltransferase, UGT1A3LPP protein, humanLIM Domain Proteins

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.
  • Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.
  • Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland.
  • Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
  • University of Tübingen, Tübingen, Germany.
  • Department of Clinical Pharmacology, University of Tübingen, Tübingen, Germany.

ORCID-Profile: Anssi J H Mykkänen, Mikko Neuvonen, Maria Paile-Hyvärinen, Tuomas O Lilius, Tuija Tapaninen, Matthias Schwab, Janne T Backman, Aleksi Tornio, Mikko Niemi

Förderung

  • European Research Council
  • Sigrid Juséliuksen Säätiö
  • Robert Bosch Stiftung

Zitieren

APA

Mykkänen, A. J. H., Tarkiainen, E. K., Taskinen, S., Neuvonen, M., Paile-Hyvärinen, M., Lilius, T. O., Tapaninen, T., Klein, K., Schwab, M., Backman, J. T., Tornio, A., & Niemi, M. (2024). Genome‐Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1 , UGT1A3 , and LPP. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3236

Vancouver

Mykkänen AJH, Tarkiainen EK, Taskinen S, Neuvonen M, Paile-Hyvärinen M, Lilius TO, et al. Genome‐Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1 , UGT1A3 , and LPP. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3236

BibTeX
@article{Mykknen2024,
  author = {Mykkänen, Anssi J H and Tarkiainen, E Katriina and Taskinen, Suvi and Neuvonen, Mikko and Paile-Hyvärinen, Maria and Lilius, Tuomas O and Tapaninen, Tuija and Klein, Kathrin and Schwab, Matthias and Backman, Janne T and Tornio, Aleksi and Niemi, Mikko},
  title = {Genome‐Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1 , UGT1A3 , and LPP},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3236}
}
Kostenlos starten →